| Product Code | DAT17994 |
|---|---|
| Publication Date | December 2009 |
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 24 |
The future of the life sciences industry relies on creating a multi-channel marketing strategy, which includes combining traditional practices with new marketing channels, such as the internet and social media sites. However, with a lack of guidance from the Food and Drug Administration on what type of communication is allowed, executives are cautious about venturing onto the web.
Rather than using the internet as a promotional tool, the pharma industry will fair better in a social media environment if they build a trusting relationship with consumers through education. Non-promotional engagement with consumers will also allow companies to listen and respond to patients' needs better.
In order for pharma to truly reap the benefits of the internet and social media sites, companies must spend some time improving their image and gaining back the trust of the public. Only then will the industry be able to move forward in implementing social media as part of their DTC strategy.
Social media is here to stay, and both the FDA and the industry are finally listening. Regardless of what guidance the FDA puts out, life sciences companies have a social responsibility to engage and educate consumers about disease and treatment options. This information empowers patients with the right tools to improve physician interactions.
PDF:Delivered by email usually within 4 to 8 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.
© 2010| Report Buyer is a trading name for Piribo Ltd. Registered in England and Wales No. 05051530 | VAT Reg No. GB 839 4556 85